Lifelong Anticoagulation is Strongly Recommended
This patient should remain on indefinite (lifelong) anticoagulation. The combination of one unprovoked DVT plus a recurrent DVT—even if the second was provoked—in the setting of heterozygous Factor V Leiden and varicose veins creates a high-risk profile that warrants extended-phase anticoagulation without a predefined stop date 1.
Rationale Based on Guidelines
The Unprovoked DVT Drives the Decision
The 2021 CHEST guidelines provide clear direction: patients with unprovoked VTE should be offered extended-phase anticoagulation (strong recommendation, moderate-certainty evidence) 1. The first DVT being unprovoked is the critical factor here—this alone establishes the indication for indefinite therapy after completing the initial 3-month treatment phase 1.
The guideline explicitly states that the recommendation to "offer" extended therapy does not mean all patients must accept it, but emphasizes that patient preference and bleeding risk should influence the final decision 1. However, given this patient has already experienced recurrence, the risk-benefit calculation heavily favors continued anticoagulation.
The Recurrent Event Reinforces the Need
While the second DVT was provoked, recurrence itself is a powerful predictor of future events. The 2020 ASH guidelines note that the majority of patients with unprovoked VTE should receive indefinite anticoagulation 2. Having a second event—regardless of provocation status—demonstrates this patient's thrombotic tendency is clinically significant.
Factor V Leiden and Varicose Veins as Persistent Risk Factors
The CHEST guidelines specifically address VTE "provoked by persistent risk factor" and recommend extended-phase anticoagulation in this scenario 1. Both heterozygous Factor V Leiden and varicose veins qualify as persistent (non-transient) risk factors:
Heterozygous Factor V Leiden: While older data suggested heterozygous carriers had similar recurrence rates to non-carriers 3, more recent evidence shows this mutation significantly increases recurrence risk, especially when combined with other risk factors 4, 5. The DAMOVES score identified heterozygous Factor V Leiden/Prothrombin mutation as having an HR of 13.86 for recurrence 4.
Varicose veins: These confer a 4.14-fold increased risk of VTE recurrence 4 and represent a 7.33-fold increased risk of DVT development 6. This is a persistent anatomical risk factor that cannot be eliminated.
Recommended Anticoagulation Regimen
Use reduced-dose DOAC as first-line therapy:
- Apixaban 2.5 mg twice daily OR Rivaroxaban 10 mg once daily 1
- These reduced doses are preferred over full-dose anticoagulation for extended-phase therapy (weak recommendation, very low-certainty evidence) 1
- If DOACs are contraindicated or not tolerated, use warfarin (target INR 2.5) 1
Ongoing Management
- Annual reassessment of the anticoagulation decision is required, particularly with significant health status changes 1
- Bleeding risk assessment should be performed regularly, as this is the primary competing risk
- The patient should understand that "extended-phase" means no predefined stop date, though the long-term risk-benefit beyond 2-4 years remains somewhat uncertain 1
Common Pitfalls to Avoid
Do not stop anticoagulation based solely on the heterozygous Factor V Leiden status—older literature suggesting benign recurrence risk is contradicted by more recent data showing significant risk when combined with other factors 4, 5
Do not use prognostic scores routinely to decide on stopping anticoagulation in this patient—the ASH guidelines suggest against routine use of HERDOO2, Vienna, DASH scores, D-dimer testing, or residual vein thrombosis ultrasound for this purpose 2
Do not classify this as "provoked only" because the second event had a trigger—the first unprovoked event establishes the indication for indefinite therapy
Do not underestimate varicose veins as a risk factor—they represent a persistent anatomical predisposition to thrombosis 4, 6